The FDA grants Fast Track designation to CDI-988, an oral antiviral for the treatment and prophylaxis of norovirus infection in adult patients.

Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being ...

BOTHELL, Wash., March 09, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces the first subjects have been dosed in a Phase 1b norovirus challenge ...

FDA Fast Track designation supports accelerated development and expedites regulatory reviewNorovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion in ...

On April 10 the Washington State Department of Health advised the FDA of a recall of certain shellfish because of norovirus-like illnesses associated with consumption of raw oysters.  The recall ...

From classrooms to workplaces, a nasty stomach virus is circulating again, and North Texas doctors say they're bracing for more cases this month. The norovirus, often mistaken for the stomach flu, ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...

Nearly 100 passengers and four crew members on a Royal Caribbean cruise ship have fallen ill with norovirus, a highly contagious stomach infection. The ship docked in Miami early Monday morning after ...

FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million global cases each year and approximately $60 billion ...